MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Wednesday, March 18, 2009

Apitope announces licensing agreement for ATX-MS-1467

Apitope, a Bristol University spinout company that is looking at a potential therapy for people with Multiple Sclerosis (MS), has announced a licensing agreement for up to 154 million in upfront, development and commercialisation milestone payments, in addition to royalties, to develop its peptide therapeutic for the treatment of MS.

Apitope founded by Professor David Wraith in the University Department of Cellular and Molecular Medicine, has granted exclusive worldwide rights to Merck Serono to develop and commercialise Apitope peptide therapeutic product, ATX-MS-1467. Apitope is eligible to receive up to 154 million in upfront, development and commercialisation milestone payments, in addition to royalties on the net sales of products resulting from the collaboration.

» Read More


============================================

No comments: